Abstract
This descriptive study used the Japanese spontaneous reporting data to investigate the time taken (TTILD) to development of interstitial lung disease (ILD) after initiation of chemotherapy and the death rates attributed in part to post-chemotherapy ILD (i.e., DR) for anticancer drugs. We evaluated TTILD and DR endpoints for 36 anticancer drugs, which are widely used for treating 11 solid and 3 hematological cancers, and are suspected of causing ILD, by using 8- year spontaneous reporting data recording for 2,553 patients in the reporting system of the relevant Japanese regulatory agency. The median TTILD and overall DR attributable to post-chemotherapy ILD for the drugs were 1.8 months and 29%, respectively. For most drugs, the median TTILDs were between 1 to 4 months, and the DRs attributable to postchemotherapy ILD were <40%; however, TTILDs were as long as 4 to 6 months and DRs attributable to postchemotherapy ILD were ≥40% for several other drugs. Of the 36 drugs, we identified those that may trigger postchemotherapy late-onset ILDs or result in high DRs. The anticancer drugs that may have triggered late-onset ILDs were defined as those that caused ILD development after approximately 4 months from the initial drug administration.
Keywords: Adverse drug-reaction reporting, anticancer drug, epidemiology, interstitial lung disease, post-marketing surveillance, spontaneous report.
Current Drug Safety
Title:A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan
Volume: 9 Issue: 3
Author(s): Akihiro Hirakawa, Kan Yonemori, Yachiyo Kuwatsuka, Makoto Kodaira, Harukaze Yamamoto, Mayu Yunokawa, Akinobu Hamada, Chikako Shimizu, Kenji Tamura, Akihiko Gemma and Yasuhiro Fujiwara
Affiliation:
Keywords: Adverse drug-reaction reporting, anticancer drug, epidemiology, interstitial lung disease, post-marketing surveillance, spontaneous report.
Abstract: This descriptive study used the Japanese spontaneous reporting data to investigate the time taken (TTILD) to development of interstitial lung disease (ILD) after initiation of chemotherapy and the death rates attributed in part to post-chemotherapy ILD (i.e., DR) for anticancer drugs. We evaluated TTILD and DR endpoints for 36 anticancer drugs, which are widely used for treating 11 solid and 3 hematological cancers, and are suspected of causing ILD, by using 8- year spontaneous reporting data recording for 2,553 patients in the reporting system of the relevant Japanese regulatory agency. The median TTILD and overall DR attributable to post-chemotherapy ILD for the drugs were 1.8 months and 29%, respectively. For most drugs, the median TTILDs were between 1 to 4 months, and the DRs attributable to postchemotherapy ILD were <40%; however, TTILDs were as long as 4 to 6 months and DRs attributable to postchemotherapy ILD were ≥40% for several other drugs. Of the 36 drugs, we identified those that may trigger postchemotherapy late-onset ILDs or result in high DRs. The anticancer drugs that may have triggered late-onset ILDs were defined as those that caused ILD development after approximately 4 months from the initial drug administration.
Export Options
About this article
Cite this article as:
Hirakawa Akihiro, Yonemori Kan, Kuwatsuka Yachiyo, Kodaira Makoto, Yamamoto Harukaze, Yunokawa Mayu, Hamada Akinobu, Shimizu Chikako, Tamura Kenji, Gemma Akihiko and Fujiwara Yasuhiro, A Descriptive Analysis of Post-Chemotherapy Development of Interstitial Lung Disease Using Spontaneous Reporting Data in Japan, Current Drug Safety 2014; 9 (3) . https://dx.doi.org/10.2174/1574886309666140601205940
DOI https://dx.doi.org/10.2174/1574886309666140601205940 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science NF-κB in Anti-Inflammatory Activity of Probiotics: An Update
Current Immunology Reviews (Discontinued) Latest Results for Anti-Angiogenic Drugs in Cancer Treatment
Current Pharmaceutical Design Targeting Phospholipase D-mediated Survival Signals in Cancer
Current Signal Transduction Therapy Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Retracted: miR-27b-3p Inhibits Invasion, Migration and Epithelial-mesenchymal Transition in Gastric Cancer by Targeting RUNX1 and Activation of the Hippo Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Pleiotropic Beneficial Effects of Epigallocatechin Gallate, Quercetin and Delphinidin on Cardiovascular Diseases Associated with Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry High Expression of miR-206 Predicts Adverse Outcomes: A Potential Therapeutic Target for Esophageal Cancer
Combinatorial Chemistry & High Throughput Screening Physical and Chemical Stimuli-Responsive Drug Delivery Systems: Targeted Delivery and Main Routes of Administration
Current Pharmaceutical Design MARK1 is a Novel Target for miR-125a-5p: Implications for Cell Migration in Cervical Tumor Cells
MicroRNA The Balancing Act between Colonisers and Inflammation: T regulatory and TH17 Cells in Mucosal Immunity during Otitis Media
Current Immunology Reviews (Discontinued) Therapeutic Potential of Targeting PAK Signaling
Anti-Cancer Agents in Medicinal Chemistry The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry Patent Selections:
Current Biomarkers (Discontinued) Mucosal T Cell Proliferation and Apoptosis in Inflammatory Bowel Disease
Current Drug Targets Biodistribution and Pharmacokinetics of PEG-10kDa-Cholecystokinin-10 in Rats After Different Routes of Administration
Current Drug Delivery The First Kinetic Enzymatic Resolution of Methyl Ester of C75
Letters in Organic Chemistry Screening Methods for Antioxidants-A Review
Mini-Reviews in Medicinal Chemistry Systemic Sclerosis Associated Interstitial Lung Disease
Current Respiratory Medicine Reviews CD44-Targeting for Antitumor Drug Delivery: A New SN-38-Hyaluronan Bioconjugate for Locoregional Treatment of Peritoneal Carcinomatosis
Current Cancer Drug Targets